| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Dividendenbekanntmachungen (15.04.2026) | 3.841 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5342 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1109 CAD 0,0683 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| Mi | Aktien unter Druck, aber mit deutlichem Potenzial - dynaCERT Inc., Eli Lilly, K+S, Novo Nordisk | 1.115 | Der Finanzinvestor | Am Wochenende scheiterten die Verhandlungen zur Beendigung des Krieges zwischen den USA und dem Iran, doch schon Ende dieser Woche soll es bereits eine nächste Verhandlungsrunde geben. Das machte sich... ► Artikel lesen | |
| Mi | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | 825 | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| Mi | JEFFERIES stuft NOVO NORDISK auf 'Hold' | 736 | dpa-AFX-Analyser | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Novo Nordisk auf "Hold" mit einem Kursziel von 270 dänischen Kronen belassen. Die Nachfragen der US-Zulassungsbehörde FDA... ► Artikel lesen | |
| Mi | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | 680 | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Mi | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | 499 | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| Mi | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | 469 | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| Mi | Aurora & Co. vor Höllenritt: Tilray schon durch, aber Berichtssaison könnte Cannabis-Aktien beben lassen | 453 | wallstreetONLINE | © Foto: adobe.stock.comDie Quartalsberichtssaison läuft an. Noch plätschert sie vergleichsweise gemächlich dahin. Zunächst stehen die US-Banken im Fokus. Doch in wenigen Tagen wird es auch im Cannabis-Sektor... ► Artikel lesen | |
| Mi | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | 452 | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen | |
| Mi | Cosmos Health Inc.: Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Gro | 445 | ACCESS Newswire | Scaled contract manufacturing division, securing long-term agreements for over 12 million unitsExpanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders... ► Artikel lesen | |
| Mi | Cosmo Pharmaceuticals N.V.: Phase III 12-Month Data for Clascoterone 5% Topical Solution Confirm Positive Safety for Chronic Use and Continued Hair Growth, both of which are Statistically Significant | 430 | Newsfile | Ad hoc announcement pursuant to Art. 53 LR Long-term safety profile comparable to vehicle supports suitability for chronic use in a lifelong condition. Patients who remained on continuous... ► Artikel lesen | |
| Mi | Medexus Pharmaceuticals Inc.: Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation | 395 | Newsfile | Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 15, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today provided an operational business update on the ongoing commercialization... ► Artikel lesen | |
| Mi | Merck & Co. (MRK): Die Bullen lauern an der 20-Tagelinie! | 373 | ratgeberGELD.at | Konsolidierung auf hohem Niveau! Rückblick Die Aktie von Merck befindet sich in einer Korrekturphase innerhalb eines starken Aufwärtstrends. Der Markt "atmet durch", nachdem die Kurse schnell gestiegen... ► Artikel lesen | |
| Mi | Svetlana Mojsov, one of the Scientists behind Ozempic, and Mathematician Carlos Kenig, who Decoded Laws of Motion, Honored as King Faisal Prize 2026 Laureates | 361 | GlobeNewswire (Europe) | The Landmark 48th Session of the Prize Comes as the King Faisal Foundation Marks 50 Years of ImpactRiyadh, Saudi Arabia, April 15, 2026 (GLOBE NEWSWIRE) -- On the evening of April 15, HRH Prince Turki... ► Artikel lesen | |
| Mi | Sandoz Group AG: Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets | 351 | EQS Group (EN) | Sandoz Group AG
/ Key word(s): Agreement
Sandoz signs landmark agreement with Rwandan government to ensure stable provision of critical medicines across selected African markets... ► Artikel lesen |
| Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
|---|---|---|---|---|---|---|
| PERRIGO | 9,670 | 0,98 | +10,13 % | 0,29 | 02.03.2026 | |
| SANOFI | 81,13 | 3,92 | +4,83 % | 4,12 | 05.05.2026 | |
| NOVO NORDISK | 34,495 | 1,57 | +4,55 % | 7,95 | 27.03.2026 | |
| SINOPHARM | 2,229 | 0,08 | +3,59 % | 0,79 | 23.06.2026 | |
| CHUGAI PHARMACEUTICAL | 45,690 | 1,46 | +3,20 % | 66,00 | 29.06.2026 | |
| NOVARTIS | 129,18 | 4,11 | +3,18 % | 3,70 | 10.03.2026 | |
| GSK | 24,490 | 0,76 | +3,10 % | 0,18 | 19.02.2026 | |
| ROCHE HOLDING | 356,80 | 10,85 | +3,04 % | 9,80 | 12.03.2026 | |
| CSPC PHARMA | 1,000 | 0,03 | +3,00 % | 0,15 | 24.06.2026 | |
| KYOWA KIRIN | 13,300 | 0,33 | +2,48 % | 35,00 | 29.06.2026 |